GATA21 Antibody

Clarification of Terminology and Scope

The term "GATA21 Antibody" appears to conflate two distinct contexts:

• Animal GATA Antibodies: Primarily targeting GATA2 or GATA5, these are well-characterized immunological reagents used in human/mouse/rat studies.

• Plant GATA21/22 Genes: Found in Arabidopsis, these transcription factors regulate growth and defense but lack published antibody-specific data in the provided sources.

This article focuses on GATA2 and GATA5 antibodies, which dominate the literature, while addressing plant GATA21/22 findings where applicable.

GATA2 Antibodies: Applications and Characteristics

GATA2 is a key transcription factor in hematopoiesis and endothelial development. Below are key details from validated antibodies:

Example Use Cases:

• Cancer Research: GATA2 antibodies detect expression in leukemia (KG-1, K562) and neuroblastoma (SH-SY5Y) cells .

• Developmental Studies: IHC localizes GATA2 to endothelial nuclei in human duodenum .

GATA5 Antibodies: Functional Insights

GATA5 regulates gastrointestinal and endothelial development. Key characteristics include:

Notable Findings:

• Gastrointestinal Expression: Detected in HepG2 (hepatocellular carcinoma) and HEK293 (embryonic kidney) cell lysates .

• Epigenetic Regulation: ChIP assays confirm binding to mucin4 promoter regions .

Plant GATA21/22: Emerging Roles in Defense and Growth

While no antibodies for GATA21 have been documented, Arabidopsis GATA21/22 genes exhibit contrasting roles:

Key Insight: These transcription factors integrate biotic stress signals with developmental processes, highlighting their potential as targets for agricultural biotechnology.

Molecular Weight Markers and Secondary Antibody Interactions

GATA antibodies often rely on secondary antibodies for detection. A novel molecular weight marker (M&R LE) containing mouse/rabbit IgG Fc epitopes enables auto-detection in Western blots :

Advantage: Eliminates primary antibody-specific secondary conjugates, streamlining multiplex assays .

Therapeutic Antibodies Targeting GATA-Related Pathways

While not directly targeting GATA transcription factors, TA-MUC1/EGFR-targeting antibodies (e.g., gatipotuzumab) demonstrate safety and antitumor activity in refractory cancers . This approach highlights the broader therapeutic potential of GATA-associated biomarkers.